OMER – omeros corporation (US:NASDAQ)
Stock Stats
News
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Omeros Announces First Commercial Sales of YARTEMLEA®
Thrombotic Microangiopathy Global Clinical Trials Market Review Report 2025 [Yahoo! Finance]
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Form 4 OMEROS CORP For: Feb 18 Filed by: Demopulos Gregory A MD
Form SCHEDULE 13G OMEROS CORP Filed by: VANGUARD GROUP INC
Form 4 OMEROS CORP For: Jan 12 Filed by: Borges David J.
Form 144 OMEROS CORP Filed by: Borges David J.
Form 144 OMEROS CORP Filed by: Borges David J.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.